Panacea Biotec Ltd. — M&A Activity 2022

Feb 1, 2022

**Headsofdisclosure **	**Headsofdisclosure **	Disclosure
The amount and percentageofthe!Inthelastfinancialyear,the DomesticBusiness
tumover or revenue or	incomeand	AssetsgeneratedtumoverofRs.219.85Crore,
networth contributedby such unit		whichismore than:
or divisionofthe listed entityduring		•63.75%oftherevenueofPBPL;
the last financial year.		•Thebook valueof Domestic Business Assets was
		negligibleandthepercentage of networthwas
		notmeasurableasthenet worth of PBPLwas
		negative;
		•35.19%oftherevenueoftheCompany (ona
		consolidatedbasis);and
		•ThebookvalueofDomesticBusinessAssetswas
		negligibleand thepercentageofnet worthwas
		notmeasurableasthenetworthoftheCompany
		(on aconsolidatedbasis)wasnegative.
~------------------------~-----------------
The date on which the agreement for		PBPL,theCompanyand theBuyerhaveenteredinto
sale has been entered into		thebindingtermsheet on January31,2022
		**("BindingTerm **Sheet").
		Underthe BindingTermSheet,the partiesare
		endeavouringtoexecute theasset purchase
		agreement (andotherdefinitivedocuments)for the
		Transactiononorprior toFebruary27,2022 (or such
		otherlaterdate asmaybeagreedby the parties).
The expected dateofcompletion of		TheTransaction isexpected tobecompletedinthe
sale/disposal		currentfinancialyear.
Consideration receivedfromsuch		Rs.l,908CroreplusGST,subjecttoanyadjustments
sale/disposal		asmay beagreedbythe partiesundertheasset
		purchaseagreement(andotherdefinitive
		documents).
	-
Briefdetails ofbuyers	and whether	MankindPharmaLimited("Buyer").
anyofthe buyers belong to the		TheBuyerdoesnotbelongtothepromoter/
promoter/promoter	group/group	promotergroup/groupcompanies.
companies.Ifyes,details thereof.

==> picture [28 x 4] intentionally omitted <==

==> picture [100 x 44] intentionally omitted <==